Trials

Trial Name Status
TB Host Directed Therapy (TBHDT) enrolling
TB-PRACTECAL enrolling
NexGen EBA enrolling
RIFASHORT enrolling
ACTG 5343 Bedaquiline - Delamanid with MBT for MDR enrolling
Bedaquiline - Linezolid with OBR MDR (NExT Trial) enrolling
endTB enrolling
ReDEFINe High-Dose RIF for Meningitis in data analysis
TBTC Study 31 ACTG 5349 4-month treatment regimens enrolling
Rifapentine TBTC Study 29 published
TBA 354 Phase 1b Multiple Ascending Dose Study With a Dose Formulation Comparison Cohort to Evaluate the Safety, Tolerability, and Pharmacokinetics of TBA-354 in Healthy Adult Subjects early termination
TBA-354 Phase 1a Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of TBA-354 in Healthy Adult Subjects all patients enrolled
Celecoxib Clinical Study WBA in data analysis
AZD5847 Randomized, Open Label, Multiple Dose Phase 2a Study of the Early Bactericidal Activity of AZD5847 in Adults With Pulmonary Tuberculosis published
HIRIF enrolling
PanACEA-MAMS-TB-01 all patients enrolled
NZT001 14-day EBA enrolling
Q203 Phase 1b Q203-TB-PI-US002 enrolling
Q203 Phase 1a Q203-TB-PI-US001 in data analysis
NiX-TB enrolling
A Phase 2 Trial to Evaluate the Efficacy and Safety of Linezolid in Tuberculosis Patients enrolling
PanACEA - RUNMC - HR1 2007.23011.01 published
NC005 enrolling
TBTC Study 26: Effectiveness and Tolerability of Weekly Rifapentine/Isoniazid for 3 Months Versus Daily Isoniazid for 9 Months for the Treatment of Latent Tuberculosis Infection published
TBTC Study 33/iAdhere: AdherenceC in data analysis
Perchlozone tablets submitted for publication
TBTC Study 32, Opti-Q enrolling
NC-003 published
Meropenem, Faropenem Phase 2 EBA, TASK-001 published
Faro-WBA submitted for publication
Safety and efficacy of blocking IL-4 with pascolizumab in patients receiving standard combination therapy for pulmonary tuberculosis (TB): a randomized, double-blind, placebo-controlled, proof-of-conc enrolling
Single Dose, Phase 1 published
Multiple Dose, Phase 1 published
NIH: A Phase I Open-Label Trial To Investigate the Pharmacokinetic Interaction Between Rifabutin Or Rifampin And A Single Dose Of TMC207 In Healthy Subjects published
NC003 enrolling
STAND all patients enrolled
NC001 submitted for publication
B1171001 published
Effect of PA-824 and PA-824 plus Moxifloxacin on the QTc Interval in Health Volunteers in data analysis
ACTG 5306 Phase I, Three-Arm Safety, Tolerability, and Pharmacokinetic Interaction Study of PA-824, an Investigational Nitroimidazole for the Treatment of Tuberculosis, Together With Efavirenz, Ritona enrolling
Evaluation of Early Bactericidal Activity in Pulmonary Tuberculosis in data analysis
Traitement du Sida submitted for publication
Phase 1 Effect of PA-824 and PA-824 plus Moxifloxacin on the QTc Interval in Health Volunteers in data analysis
ACTG 5306 Phase I Evaluating the Safety and Drug Interaction of PA-824, an Investigational Tuberculosis Medication, Together With Efavirenz, Ritonavir-Boosted Lopinavir, or Rifampin enrolling
Phase 2 Evaluation of Early Bactericidal Activity in Pulmonary Tuberculosis published
Evaluation of Early Bactericidal Activity in Pulmonary Tuberculosis published
NC003 Evaluation of Early Bactericidal Activity in Pulmonary Tuberculosis With Clofazimine (C)-TMC207 (J)-PA-824 (Pa)-Pyrazinamide (Z) enrolling
NC001 Evaluation of Early Bactericidal Activity in Pulmonary Tuberculosis With(J-M-Pa-Z) submitted for publication
NC002 Phase II Trial to Evaluate the Efficacy, Safety and Tolerability of the Following: PA-824 Plus Moxifloxacin Plus Pyrazinamide in Drug Sensitive and Multi-Drug Resistant Patients
Controlled comparison of two moxifloxacin containing treatment shortening regimens with the standard regimen in pulmonary TB all patients enrolled
A Controlled Trial of a 4-Month Quinolone-Containing Regimen for the Treatment of Pulmonary Tuberculosis. all patients enrolled
Phase 2 Placebo-controlled, Randomized Study of Oral Immunomodulator in TB and TB/HIV Patients enrolling
B1171002 published
B1171003 published
NC002
Pediatric PK and Safety Trial Delamanid in MDR TB enrolling
Delamanid with OBR for MDR TB in data analysis
242-07-204 published
TMC207-TBC211 study in development
TMC207TBC1002 published
STREAM Trial Stage 2 enrolling
TMC207-TiDP13-C209 published
TMC207-TiDP13-208 published
TBTC Study 30PK Linezolid Pharmacokinetics and Pharmacodynamics in the Treatment of Multi-Drug Resistant and Extensively-Drug Resistant Tuberculosis submitted for publication
TBTC Study 30: A Phase I/II Pilot Study for Evaluation of Low Dose, Once Daily, Linezolid Plus Optimized Background Therapy (OBT) Versus Placebo Plus OBT for the Treatment of Multi-drug Resistant Tube submitted for publication
09-0111 N01AI80024C published
SQ109-CP001 published
LMU-IMPH-SQ109-01 published
PanACEA-MAMS-TB-01 published
A Phase IIa, Open Label Study to Determine the EBA, Extended EBA and Pharmacokinetic Study of LL3858 for the Treatment of Newly Diagnosed Sputum Smear-Positive Pulmonary TB study in development